Immunotherapy and targeted therapy combinations in metastatic breast cancer

FJ Esteva, VM Hubbard-Lucey, J Tang… - The lancet oncology, 2019 - thelancet.com
Immunotherapy is emerging as a new treatment modality in breast cancer. After long-
standing use of endocrine therapy and targeted biological therapy, improved understanding …

Molecular subtypes and local-regional control of breast cancer

SM Fragomeni, A Sciallis… - Surgical Oncology …, 2018 - surgonc.theclinics.com
Breast cancer is a heterogeneous disease that affects one anatomic site, yet is
phenotypically variable. 1, 2 The identification of different biological subtypes occurs …

[HTML][HTML] Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast …

L Gianni, CS Huang, D Egle, B Bermejo, C Zamagni… - Annals of …, 2022 - Elsevier
Background High-risk triple-negative breast cancers (TNBCs) are characterized by poor
prognosis, rapid progression to metastatic stage and onset of resistance to chemotherapy …

Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer

MCA Wouters, BH Nelson - Clinical Cancer Research, 2018 - AACR
There is abundant evidence that tumor-infiltrating CD8+ T cells contribute positively to
antitumor immunity; however, the role of tumor-infiltrating B cells (TIL-B) and plasma cells …

[HTML][HTML] Immunological differences between primary and metastatic breast cancer

B Szekely, V Bossuyt, X Li, VB Wali, GA Patwardhan… - Annals of …, 2018 - Elsevier
Background Little is known about how the immune microenvironment of breast cancer
evolves during disease progression. Patients and methods We compared tumor infiltrating …

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

A Sistigu, T Yamazaki, E Vacchelli, K Chaba, DP Enot… - Nature medicine, 2014 - nature.com
Some of the anti-neoplastic effects of anthracyclines in mice originate from the induction of
innate and T cell–mediated anticancer immune responses. Here we demonstrate that …

The immune contexture in human tumours: impact on clinical outcome

WH Fridman, F Pagès, C Sautès-Fridman… - Nature Reviews …, 2012 - nature.com
Tumours grow within an intricate network of epithelial cells, vascular and lymphatic vessels,
cytokines and chemokines, and infiltrating immune cells. Different types of infiltrating …

[HTML][HTML] Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early …

A Goldhirsch, WC Wood, AS Coates, RD Gelber… - Annals of oncology, 2011 - Elsevier
Abstract The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel
adopted a new approach to the classification of patients for therapeutic purposes based on …

Cancer classification using the Immunoscore: a worldwide task force

J Galon, F Pagès, FM Marincola, HK Angell… - Journal of translational …, 2012 - Springer
Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation
of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor …

Molecular characterization of basal‐like and non‐basal‐like triple‐negative breast cancer

A Prat, B Adamo, MCU Cheang, CK Anders… - The …, 2013 - academic.oup.com
Abstract Learning Objectives Contrast the definitions of TN and basal‐like. Describe the
undistinguishable global gene expression patterns of non‐basal‐like TN tumors versus non …